Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Addressing the imbalances & disparities amid COVID-19

Kenneth Anderson • 4 May 2020
COMy Virtual 2020
Multiple Myeloma Bortezomib BTK inhibitors Ibrutinib Selinexor

Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the ongoing COVID-19 pandemic and how it has impacted research and clinical practice. Additionally, Dr Anderson addresses research that is being applied from multiple myeloma into COVID-19. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Kenneth Anderson

1:27
Collaboration in the myeloma community
Kenneth Anderson • 14 May 2022
4:04
The future of myeloma treatment and the possibility of cure
Kenneth Anderson • 14 May 2022
3:41
Can novel immunotherapies cure multiple myeloma?
Kenneth Anderson • 15 Dec 2020
4:00
Bortezomib-induced immunogenic cell death in myeloma
Kenneth Anderson • 15 Dec 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals